• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Consumer Cyclical·2367.HK
Share

Giant Biogene Holding Co., Ltd. Stocks

HK$ 26.72Last Updated 10.07.2026

Issuer Rating

6/7
Performance

Strong

Risk

Limited

Recommendation

Buy

Market Cap

HK$ 3.61B

HK$ 26.72
Key Takeaways

Risk factor

Good trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Giant Biogene Holding Co., Ltd. operates as an investment holding entity, primarily engaged in the research, development, production, and sale of beauty and wellness products based on bioactive materials throughout the People's Republic of China. The company also manufactures functional foods leveraging rare ginsenosides technology and provides medical devices. Its diverse product range, which includes specialized skincare, medical dressings, and nutritional supplements, is marketed predominantly under brand names such as Comfy, Collgene, Keyu, Kehen, Kefuping, Leeyen, SKIGIN, and Shengan. Established in 2000, Giant Biogene Holding Co., Ltd. maintains its headquarters in Xi'an, PRC.

Company Valuation

Slightly undervalued
5/7

Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBIT

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 2367.HK is 40.8 and suggests 56.8% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.07.2026 21:00

SK Hynix's Debut, Shein's New Plan, and Logistics Companies from Uzbekistan: Key IPO Updates as of July 12

12.07.2026 18:01

"Buffett in a Skirt": How Hetty Green Built an Empire on Crises and Saved Wall Street

12.07.2026 15:01

"The 30-Second Rule": How Investors Can Learn to Think Things Through Before Making Trades

12.07.2026 05:26

The U.S. announced a third wave of strikes against Iran following the closure of the Strait of Hormuz

11.07.2026 19:01

A Triumph for City Governments? How China’s Scaling Model Will Change the Global AI Market

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026